Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Deep rTMS and Varenicline for Smoking Cessation
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 50
- Registration Number
- NCT04083144
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- University of Zagreb
- Target Recruit Count
- 352
- Registration Number
- NCT04015414
- Locations
- 🇭🇷
University of Zagreb School of Medicine, Zagreb, Croatia
🇸🇮University of Ljubljana School of Medicine, Ljubljana, Slovenia
Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
- Conditions
- Interventions
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 39
- Registration Number
- NCT04011280
- Locations
- 🇺🇸
Pacific Treatment & Research Center at UCSD, La Jolla, California, United States
UH3 Varenicline for Cannabis Use Disorder
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 174
- Registration Number
- NCT03980561
- Locations
- 🇺🇸
Behavioral Health Services of Pickens County, Pickens, South Carolina, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Using Non-invasive Brain Stimulation (tDCS) With Varenicline for Treating Tobacco Dependence
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Centre for Addiction and Mental Health
- Target Recruit Count
- 41
- Registration Number
- NCT03841292
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders
- Conditions
- Interventions
- Locations
- 🇪🇸
Galatea Clinic, Barcelona, Spain
🇪🇸Hospital de Sant Pau, Barcelona, Spain
🇪🇸Sant Rafael Hospital, Barcelona, Spain
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 34
- Registration Number
- NCT03722966
- Locations
- 🇺🇸
TSET Health Promotion Research Center, Oklahoma City, Oklahoma, United States
Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 80
- Registration Number
- NCT03538808
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
PRecision Interventions for SMoking in the SCCS
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 67
- Registration Number
- NCT03521141
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1
- First Posted Date
- 2018-04-24
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Brown University
- Target Recruit Count
- 5
- Registration Number
- NCT03507127
- Locations
- 🇺🇸
Brown University, 121 South Main Street, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.